Healthcare >> CEO Interviews >> May 6, 2002
LOUIS R. LAMONTAGNE is President and Chief Executive Officer of
Neurochem, Inc. Dr. Lamontagne oversees Neurochem's management
team and is responsible for setting the company's vision and
strategies for drug development, manufacturing, and regulatory
affairs. Dr. Lamontagne holds a PhD in Immunochemistry and
Immunology from McMaster University, Hamilton and a BSc Honours
in Chemistry from Queen's University, Kingston. Dr. Lamontagne's
academic studies focused on the induction of acute phase
reactants (serum amyloid A and P, CRP, etc.). After his PhD, Dr.
Lamontagne joined Harvard University School of Public Health to
research tropical parasitic diseases. In the biotechnology
sector, Dr. Lamontagne held several senior positions (including
Director of R&D and Product Development) at Chembiomed Ltd., a
biotechnology company involved in the development of therapeutic
products for the treatment of Hemolytic Disease of the newborn
and for the prevention of organ rejections in ABO incompatible
transplants. Dr. Lamontagne has also held several other key
management positions, including Director, Institute for
Biological Sciences at the National Research Council and
President and Chief Executive Officer, Ottawa Life Sciences
Technology Centre. Profile
Dr. Lamontagne: Neurochem was founded in 1993 by Queen's
University in Kingston, Ontario, Canada. The company was formed
on the
